Context Therapeutics Inc. (CNTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Context Therapeutics Inc. (CNTX) closed at USD 0.26 on 2026-10-14, a change of -78.1 % over the past year, with a market capitalization of USD 22.1M.

Context Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Context Therapeutics Inc. key figures

Previous close

USD 0.26 (2026-10-14)

1-year change

-78.1 %

Market cap

USD 22.1M

Enterprise value

USD -20.65M

P/E ratio (trailing)

-0.59

P/E ratio (forward)

-0.55

EPS (trailing)

-0.41

EPS (forward)

-0.44

PEG ratio

n/a

Price to book

0.58

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.89

Employees

15

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Context Therapeutics Inc.

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Context Therapeutics Inc. and compare it with other stocks.